No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	valemetostat Sensitive: A1 - Approval valemetostat Sensitive : A1	valemetostat Sensitive: A1 - Approval valemetostat Sensitive : A1
ARID1A mutation	Endometrial Cancer	ARID1A mutation	Endometrial Cancer	DZR123 Sensitive: B - Late Trials DZR123 Sensitive : B	DZR123 Sensitive: B - Late Trials DZR123 Sensitive : B
ARID1A mutation	Ovarian Cancer	ARID1A mutation	Ovarian Cancer	DZR123 Sensitive: C2 – Inclusion Criteria DZR123 Sensitive : C2	DZR123 Sensitive: C2 – Inclusion Criteria DZR123 Sensitive : C2
EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	valemetostat Sensitive: C2 – Inclusion Criteria valemetostat Sensitive : C2	valemetostat Sensitive: C2 – Inclusion Criteria valemetostat Sensitive : C2
TP63 rearrangement	Lymphoma	TP63 rearrangement	Lymphoma	valemetostat Sensitive: C4 – Case Studies valemetostat Sensitive : C4	valemetostat Sensitive: C4 – Case Studies valemetostat Sensitive : C4
EZH2 Y641	Lymphoma	EZH2 Y641	Lymphoma	HM97594 Sensitive: D – Preclinical HM97594 Sensitive : D	HM97594 Sensitive: D – Preclinical HM97594 Sensitive : D
EZH2 Y641F	Melanoma	EZH2 Y641F	Melanoma	UNC1999 Sensitive: D – Preclinical UNC1999 Sensitive : D	UNC1999 Sensitive: D – Preclinical UNC1999 Sensitive : D
AR mutation	Prostate Cancer	AR mutation	Prostate Cancer	DZR123 Sensitive: D – Preclinical DZR123 Sensitive : D	DZR123 Sensitive: D – Preclinical DZR123 Sensitive : D
EZH2 Y641	Diffuse Large B Cell Lymphoma	EZH2 Y641	Diffuse Large B Cell Lymphoma	DW91170 Sensitive: D – Preclinical DW91170 Sensitive : D	DW91170 Sensitive: D – Preclinical DW91170 Sensitive : D

EZH1 inhibitor

EZH1 inhibitor

Associations(9)

Associations
(9)